glp-1 gastric stasis lawsuit in louisiana Ozempic Gasteroparesis Risk Concealed By Novo Nordisk Through Misleading Marketing: Ozempic GLP-1 Lawsuit [2026]: Gastroparesis

A commission may be earned if purchases are made through these links, at no additional cost to the reader

Customer Support Channels: The company lists phone support (1-888-979-9580), email support ([email protected]), and a mobile app (available on Apple App Store and Google Play)

Are Anthem and Blue Cross the Same

But they contain different active ingredients, work through different mechanisms, and as the landmark 2025 SURMOUNT-5 trial revealed they do not produce equal results

Our major concern is the unbalance and inappropriate reductions in calorie or energy intake associated with these weight loss drugs," said Cooper, associate director of the UCI Institute for Clinical and Translational Science and interim director of the UCI Institute for Precision Health

4 A history of gallbladder disease A 2022 systematic review of 76 randomised trials found that GLP-1 medications are associated with a relative risk of around 37% for gallbladder or biliary disease, with a higher relative risk in weight-loss trials than in diabetes trials